Search research articles
Contact Us
Filters
Showing results (41-50 of 118) with videos related to
Page
of 12
Sort By:
Oncology and Therapy
|
March 2, 2026
Summary of Research: Elranatamab Fixed Dosing-A Safe, Effective, and Convenient Dosing Approach
Mohamed Elmeliegy, Pooneh Soltantabar, Jennifer Hibma, et al.
Investigational New Drugs
|
February 24, 2012
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression
Zarina J D'Costa, Cheng-Mee Leong, Justin Shields, et al.
Journal of Primary Health Care
|
November 12, 2010
HPV/cervical cancer vaccination: parental preferences on age, place and information needs
Sally B Rose, Beverley A Lawton, Tolotea Lanumata, et al.
The Journal of Investigative Dermatology
|
September 18, 2009
Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections
Cheng Mee Leong, John Doorbar, Ingo Nindl, et al.
Drug Discovery Today
|
February 15, 2011
Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration
Da-Qing Yang, Marie-Jo Halaby, Yan Li, et al.
British Journal of Clinical Pharmacology
|
December 12, 2018
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling
Jennifer E Hibma, Hagop M Kantarjian, Daniel J DeAngelo, et al.
Journal of Clinical Pharmacology
|
December 17, 2025
Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma
Pooneh Soltantabar, Jennifer Hibma, Diane Wang, et al.
NPJ Systems Biology and Applications
|
September 1, 2025
Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma
Kamrine E Poels, Mohamed Elmeliegy, Jennifer Hibma, et al.
Clinical Pharmacology and Therapeutics
|
May 10, 2019
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin
Luke K Fostvedt, Jennifer E Hibma, Joanna C Masters, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2022
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
Jennifer E Hibma, Melissa O'Gorman, Sunil Nepal, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 118) with videos related to
Sort By:
Page
of 12
Oncology and Therapy
|
March 2, 2026
Summary of Research: Elranatamab Fixed Dosing-A Safe, Effective, and Convenient Dosing Approach
Mohamed Elmeliegy, Pooneh Soltantabar, Jennifer Hibma, et al.
Investigational New Drugs
|
February 24, 2012
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression
Zarina J D'Costa, Cheng-Mee Leong, Justin Shields, et al.
Journal of Primary Health Care
|
November 12, 2010
HPV/cervical cancer vaccination: parental preferences on age, place and information needs
Sally B Rose, Beverley A Lawton, Tolotea Lanumata, et al.
The Journal of Investigative Dermatology
|
September 18, 2009
Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections
Cheng Mee Leong, John Doorbar, Ingo Nindl, et al.
Drug Discovery Today
|
February 15, 2011
Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration
Da-Qing Yang, Marie-Jo Halaby, Yan Li, et al.
British Journal of Clinical Pharmacology
|
December 12, 2018
Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling
Jennifer E Hibma, Hagop M Kantarjian, Daniel J DeAngelo, et al.
Journal of Clinical Pharmacology
|
December 17, 2025
Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple Myeloma
Pooneh Soltantabar, Jennifer Hibma, Diane Wang, et al.
NPJ Systems Biology and Applications
|
September 1, 2025
Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma
Kamrine E Poels, Mohamed Elmeliegy, Jennifer Hibma, et al.
Clinical Pharmacology and Therapeutics
|
May 10, 2019
Pharmacokinetic/Pharmacodynamic Modeling to Support the Re-approval of Gemtuzumab Ozogamicin
Luke K Fostvedt, Jennifer E Hibma, Joanna C Masters, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2022
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
Jennifer E Hibma, Melissa O'Gorman, Sunil Nepal, et al.
Page
of 12